NEOPLASMS BY HISTOLOGIC TYPE

This early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a low dose of radiation to help th…

This trial tests atezolizumab, a drug already approved for several cancers, in people with rare cancers that have high tumor mutational burden (TMB) or microsatellite instability (MSI). The goal is to see if the drug can shrink tumors or stop them from growing for at least 24 wee…

This early-stage study tests whether a new drug called ziftomenib is safe when combined with standard chemotherapy for people whose acute myeloid leukemia (AML) has come back or not responded to treatment. The study includes adults with specific genetic changes (NPM1 mutation or …

This trial tests capmatinib, a drug already approved for certain lung cancers, in adults with rare cancers that have specific MET gene changes. About 30 participants will receive the drug to see if it can shrink tumors or stop them from growing for at least 24 weeks. The goal is …

This trial is testing a drug called entrectinib (Rozlytrek) in people with rare cancers that have a specific genetic change called a ROS1 gene fusion. The drug is already approved for some lung cancers, and researchers want to see if it can help shrink or control other tumor type…

This early-stage trial tests a new gene therapy called KLN-1010 for people with multiple myeloma that has come back or stopped responding to treatment. Instead of removing cells and engineering them in a lab, this therapy works inside the body to create special immune cells that …

This study tests a drug called alectinib, already approved for some lung cancers, in people with rare cancers that have a specific genetic change called ALK. About 30 adults, teens, and children with ALK-positive cancers will receive alectinib to see if it shrinks tumors or stops…